These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8447562)

  • 1. Experience with recombinant factor VIIA in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report.
    Bell BA; Birch K; Glazer S
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):77-9. PubMed ID: 8447562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. rVIIa therapy to secure haemostasis during central line insertion in children with high-responding FVIII inhibitors.
    Smith OP; Hann IM
    Br J Haematol; 1996 Mar; 92(4):1002-4. PubMed ID: 8616058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody.
    Gringeri A; Santagostino E; Mannucci PM
    Haemostasis; 1991; 21(1):1-4. PubMed ID: 1907588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombelastography-guided factor VIIa therapy in a surgical patient with severe hemophilia and factor VIII inhibitor.
    Pivalizza EG; Escobar MA
    Anesth Analg; 2008 Aug; 107(2):398-401. PubMed ID: 18633014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired inhibitors.
    Cohen AJ; Kessler CM
    Baillieres Clin Haematol; 1996 Jun; 9(2):331-54. PubMed ID: 8800509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
    Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA
    Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors.
    Rubinger M; Houston DS; Schwetz N; Woloschuk DM; Israels SJ; Johnston JB
    Am J Hematol; 1997 Oct; 56(2):112-8. PubMed ID: 9326353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors.
    Abou-Ismail MY; Vuyyala S; Prunty J; Schmaier AH; Nayak L
    Haemophilia; 2020 Jul; 26(4):601-606. PubMed ID: 32338423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
    Doshi BS; Gangadharan B; Doering CB; Meeks SL
    PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tipping point: The critical role of therapeutic apheresis in a case of refractory acquired hemophilia.
    Losos M; Scrape S; Joshi S; Shmookler A; Chen J
    J Clin Apher; 2017 Dec; 32(6):564-566. PubMed ID: 27646211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.
    Carr ME; Loughran TP; Cardea JA; Smith WK; Kuhn JG; Dottore MV
    Int J Hematol; 2002 Jan; 75(1):95-9. PubMed ID: 11843300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin.
    Takeyama M; Nogami K; Kajimoto T; Ogiwara K; Matsumoto T; Shima M
    Int J Hematol; 2018 Jan; 107(1):112-116. PubMed ID: 28597369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant factor VIIa (NovoSeven) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors.
    Lusher JM
    Haemostasis; 1996; 26 Suppl 1():124-30. PubMed ID: 8904186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors.
    Majumdar G; Savidge GF
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1031-3. PubMed ID: 8148476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.